StreetAlpha
13F holdings · Q3 2026

Atle Fund Management AB

Stockholm, V7 · files as Atle Fund Management AB
Know the moment Atle Fund Management AB filesYou follow Atle Fund Management AB An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 12, 2026Next filing due Feb 15, 2027CIK 1381843

Atle Fund Management AB reported 39 stocks worth $373M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are LLY (9.7%), MRK (6.6%) and JNJ (6.5%). Compared with Q2 2026, the fund opened new positions in SMMT, CMPS and PVLA, added to LLY, JNJ and ABBV, trimmed MRK, RVMD and CVS and sold out of IONS, BCAX and CMPX.

Latest filing: what Atle Fund Management AB did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new18 added15 trimmed4 sold outBought about $47.6M · sold about $41.2M
New 4
Added 18
See all 18 →
Trimmed 15
See all 15 →
Sold out 4

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$373M+0.5% vs last quarter
Stocks held394 new · 4 sold out
Top 5 weight35.3%fairly concentrated
Turnover24%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
LLY
Eli Lilly & Co
$36.1M9.7%31K+1,381 (+5%)8 of 8
2
MRK
Merck & Co Inc
$24.6M6.6%169K−20K (−11%)8 of 8
3
JNJ
Johnson & Johnson
$24.2M6.5%91K+5,962 (+7%)3 of 8
4
ABBV
Abbvie Inc
$23.9M6.4%91K+27K (+42%)8 of 8
5
TMO
Thermo Fisher Scientific Inc
$23.2M6.2%34K+6,551 (+24%)8 of 8
6
BIIB
Biogen Inc
$16M4.3%71K+8,174 (+13%)2 of 8
7
VRTX
Vertex Pharmaceuticals I
$14.7M3.9%28K+9,026 (+47%)8 of 8
8
RVMD
Revolution Medicines Inc
$13.6M3.6%66K−6,964 (−10%)8 of 8
9
ONC
Beone Medicines Ltd
$13.1M3.5%36K+499 (+1%)8 of 8
10
CVS
Cvs Health Corp
$11.9M3.2%139K−6,791 (−5%)4 of 8
🔒 29 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
IONS
Ionis Pharmaceuticals Inc
$10.9M137K
BCAX
Bicara Therapeutics Inc
$4.3M146K
CMPX
Compass Therapeutics Inc
$2.3M1M
JBIO
Jade Biosciences Inc
$2M89K

Reported value

last 8 quarters
$211MQ4 '24
$227MQ1 '25
$234MQ2 '25
$27MQ3 '25
$313MQ4 '25
$310MQ1 '26
$372MQ2 '26
$373MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 12, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Atle Fund Management AB 13F FAQ

What does Atle Fund Management AB own?

Atle Fund Management AB reported 39 stocks worth $373M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are LLY (9.7%), MRK (6.6%) and JNJ (6.5%). The table above lists every position in the filing (the top 10 without an account).

What did Atle Fund Management AB buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 18 added to, 15 trimmed and 4 sold out. New positions include SMMT, CMPS and PVLA. It sold all of IONS, BCAX and CMPX.

When will Atle Fund Management AB file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Atle Fund Management AB's portfolio worth?

The Q3 2026 filing reports $373M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.